BK virus-associated hemorrhagic cystitis is a common complication of allogeneic hematopoietic stem cell transplant. It is known to be associated with cyclophosphamide therapy and the intensity of the conditioning regimen as well as infection with the BK virus. Data are limited for BK virus-associated hemorrhagic cystitis in pediatric recipients of allogeneic hematopoietic stem cell transplant. Therefore, we aimed to identify the risk factors and etiology of BK virus-associated hemorrhagic cystitis and determine the factors that may improve the treatment efficacy. Data from recipients of allogeneic hematopoietic stem cell transplant were retrospectively analyzed. These data included information about age, sex, underlying disease, the details of ablative conditioning, graft-versus-host disease prophylaxis, donor type, stem cell source, history of acute graft-versus-host disease, and cytomegalovirus reactivation. A total of 50 patients developed BK virusassociated hemorrhagic cystitis among 334 patients. Symptoms associated with BK virus-associated hemorrhagic cystitis manifested an average of 45.3 days after transplant. Most of the patients had grade 2 and grade 3 hemorrhagic cystitis. Risk factor analysis revealed that haploidentical donor type, treatment with busulfan and cyclophosphamide as part of conditioning regimen, and history of total body irradiation increased the risk of BK virus-associated hemorrhagic cystitis in the pediatric recipient population. We found that, despite current conditioning regimens, BK virus-associated infection still leads to a considerable incidence rate of hemorrhagic cystitis in pediatric recipients of allogeneic hematopoietic stem cell transplant. Patients with a haploidentical donor and a history of busulfan and cyclophosphamide treatment or total body irradiation had a higher risk of BK virus-associated hemorrhagic cystitis. Thus, we suggest that patients with these factors should be followed closely after allogeneic hematopoietic stem cell transplant.
Primary hemophagocytic lymphohistiocytosis (p-HLH) can be cured with allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether HSCT outcomes are affected by the presence of different genetic mutations. We used data obtained from children who underwent allo-HSCT for HLH to examine the effects of genetic mutations on HSCT outcomes. Data from 153 paediatric patients in 18 paediatric stem cell centres were retrospectively evaluated. Patients were divided into four groups: 1) with PRF1 mutation (n = 46), 2) with UNC13D mutation (n = 38), 3) with STX11/STXBP2 mutation (n = 25) and 4) with Griscelli syndrome type 2/ Chediak–Higashi syndrome (GS2/CHS) diagnosis (n = 44). Statistical analysis showed no difference between the subgroups in terms of engraftment, VOD, acute GVHD, chronic GVHD, TRM, OS and EFS rates. The most important factor affecting OS and EFS in all genetic subgroups was remission status before HSCT. The 5-year EFS values for children with mutations in PRF1, UNC13D, STX11/STXBP2 and GS2/CHS were 71%, 66.6%, 74% and 66.7, respectively (log-rank >0.05). However, with prospective studies covering more patients, and creating different genetic subgroups by performing more detailed genetic analyses, special approaches for different genetic subgroups can be revealed in the future.
1 January 2018 in Journal of Pediatric Hematology/Oncology
FK506 (tacrolimus) is an immunosuppressive drug and more potent than cyclosporine. FK506 is widely used for immunosuppression in the prevention and treatment of graft-versus-host disease after allogeneic bone marrow transplantation and solid organ transplantation. Neurotoxicity is a recognized complication of FK506 therapy, but ptosis and weakness of eye abduction unilaterally has not been reported in association with FK506 administration to date. We discuss a 13-year-old male patient who developed ptosis and weakness of eye abduction unilaterally 90 days after transplantation with bone marrow from an unrelated donor, for acute lymphoblastic leukemia in this case report. FK506 therapy was administered for graft-versus-host disease prophylaxis and CMV infection was treated with ganciclovir. The physical examination findings completely resolved 72 to 96 hours after concomitant FK506 and ganciclovir treatment were terminated.
Tr en Amaç: Bu çalışmada nedeni bilinmeyen ateş (NBA) tanısı almış 30 çocuk hastada etyolojinin, hastaların klinik ve laboratuvar özelliklerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Kliniğimizde bir yıllık süreçte NBA tanısı alan 30 çocuk hastanın ateş etyolojisini, tanısal yaklaşımlarını ve klinik özelliklerini içeren veriler geriye dönük olarak hasta dosyaları incelenerek elde edilmiştir. Bulgular: Hastaların median yaşı 63 ay (6-192 ay) idi. Hastaların 12’si (%40) erkek, 18’i(%60) kız idi. Başvuruda ateşin süresi median 22.5 gün (3-60 gün) idi. Ensık saptanan fizik muayene bulgusu sırasıyla %53.3 ve %40 hepotomegali ve splenomegali idi. Nedeni bilinmeyen ateş nedeni olarak 14 (%46.6) hastada enfeksiyon, 8 (26.7) hastada kollajen vasküler hastalık, 5 (%16.7) hastada malign hastalık, 1 (%3.3) hastada diğer hastalık grubundan hastalık saptandı. İki (%6.6) hastada ateşin nedeni belirlenemedi. Nedeni bilinmeyen ateşin etyolojisinde Leishmania, tüberküloz ve brusellozis enfeksiyon hastalıklarından en sık tespit edilen neden iken juvenile romatoid artrit ve akut lenfoblastik lösemi enfeksiyon dışı ensık neden idi. Sonuç: Çalışmamızda NBA’nın en sık nedeni enfeksiyon hastalıkları idi. Kollajen vasküler hastalıklar ve malign hastalıklar da NBA’nın önemli nedenlerindendir. Bize göre detaylı öykü dikkatli fizik muayene ve yakın klinik izlem uygulanacak invaziv işlemler ve invaziv olmayan test sayısını azaltacaktır. Purpose: The aim of this retrospective study is to evaluate the etiology clinical and laboratory features of fever of unknown origin (FUO) diagnosed in 30 pediatric patients. Materials and methods: The clinical data including the etiology, diagnostic approaches and clinical characteristics were retrospectively analysed in 30 pediatric patients with FUO who presented to our clinic in one year period. Results: The median age of the patients was 63 (6-192) months. Among the patients, 12 were male (40%), while 18 were female (60%). The median duration of the fever was 22.5 (3-60) days during hospital admission. The most common physical findings were hepatomegaly and splenomegaly, which were observed in 53. 3 and 40 patients, respectively. The cause of the FUO was detected to be infection in 14 patients (46.6%), connective tissue-vascular diseases in 8 patients (26.7%), malignancies in 5 patients (16.7%), and miscellaneous diseases in 1 patient (3.3%). In two patients (6.6%) the etiology could not be identified. Leishmaniasis, tuberculosis and brucellosis were the most commonly identified infections, whereas juvenile rheumatoid arthritis and acute lymphoblastic leukemia were the most common non-infectious causes. Conclusion: The most common cause of FUO in our study was infection diseases. Connective-vascular tissue diseases and malignancies are also important causes of FUO. In our opinion, detailed patient history, carefully physical examination and close clinical follow-up may reduce the number of the invasive procedures and non-invasive tests.